{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:11:22Z","timestamp":1782951082825,"version":"3.54.5"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Emergency Medicine Clinics of North America"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.emc.2025.03.008","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T19:29:19Z","timestamp":1748374159000},"page":"407-420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Thrombotic Microangiopathies"],"prefix":"10.1016","volume":"43","author":[{"given":"Ramy","family":"Hanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Gibney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Boysen-Osborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.emc.2025.03.008_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.semnephrol.2023.151345","article-title":"Onconephrology and thrombotic microangiopathy: looking beyond the horizon","volume":"42","author":"Gudsoorkar","year":"2022","journal-title":"Semin Nephrol"},{"issue":"3","key":"10.1016\/j.emc.2025.03.008_bib2","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/MNH.0000000000000499","article-title":"Atypical hemolytic uremic syndrome and complement blockade: established and emerging uses of complement inhibition","volume":"28","author":"Hanna","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"2","key":"10.1016\/j.emc.2025.03.008_bib3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.ackd.2021.11.006","article-title":"Thrombotic microangiopathy syndromes-common ground and distinct frontiers","volume":"29","author":"Hanna","year":"2022","journal-title":"Adv Chronic Kidney Dis"},{"issue":"5","key":"10.1016\/j.emc.2025.03.008_bib4","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1053\/j.ajkd.2022.10.014","article-title":"Renal Thrombotic microangiopathy: a review","volume":"81","author":"Genest","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.emc.2025.03.008_bib5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/MNH.0000000000000954","article-title":"Thrombotic microangiopathy\u2013the importance of a multidisciplinary approach","volume":"33","author":"Tran","year":"2024","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"2","key":"10.1016\/j.emc.2025.03.008_bib6","doi-asserted-by":"crossref","first-page":"7053","DOI":"10.4081\/hr.2017.7053","article-title":"Atypical hemolytic uremic syndrome: a brief review","volume":"9","author":"Zhang","year":"2017","journal-title":"Hematol Rep"},{"issue":"2","key":"10.1016\/j.emc.2025.03.008_bib7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00005792-196603000-00003","article-title":"Thrombotic thrombocytopenia purpura: report of 16 cases and review of the literature","volume":"45","author":"Amorosi","year":"1966","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.emc.2025.03.008_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.emc.2025.03.008_bib9","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1111\/jth.15006","article-title":"ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.emc.2025.03.008_bib10","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/35097008","article-title":"Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura","volume":"413","author":"Levy","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.emc.2025.03.008_bib11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/jca.21302","article-title":"Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research","volume":"29","author":"Sarode","year":"2014","journal-title":"J Clin Apher"},{"key":"10.1016\/j.emc.2025.03.008_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.emc.2025.03.008_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/10760296231207629","article-title":"The combination of the lactate dehydrogenase\/hemoglobin ratio with the PLASMIC score facilitates differentiation of TTP from septic DIC without identification of schistocytes","volume":"29","author":"Nishimura","year":"2023","journal-title":"Clin Appl Thromb Hemost"},{"issue":"4","key":"10.1016\/j.emc.2025.03.008_bib14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic pupura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.emc.2025.03.008_bib15","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2017-06-788026","article-title":"Recombinant ADAMTS- 13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura","volume":"130","author":"Scully","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.emc.2025.03.008_bib16","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s00467-020-04560-0","article-title":"Hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli in children: incidence, risk factors, and clinical outcome","volume":"35","author":"Ylinen","year":"2020","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1016\/j.emc.2025.03.008_bib17","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201ckidney disease: improving global outcomes\u201d (KDIGO) controversies conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.emc.2025.03.008_bib18","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/jcm8030407","article-title":"The extended use of eculizumab in pregnancy and complement activation(-)associated diseases affecting maternal, fetal and neonatal kidneys\u2014the future is now?","volume":"8","author":"Stefanovic","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.emc.2025.03.008_bib19","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/asheducation-2015.1.644","article-title":"Syndromes of thrombotic microangiopathy associated with pregnancy","volume":"2015","author":"George","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Programl"},{"key":"10.1016\/j.emc.2025.03.008_bib20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.preghy.2018.02.007","article-title":"Thrombotic microangiopathies of pregnancy: differential diagnosis","volume":"12","author":"Gupta","year":"2018","journal-title":"Pregnancy Hypertens"},{"issue":"12","key":"10.1016\/j.emc.2025.03.008_bib21","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200161","article-title":"Circulating angiogenic factor levels in hypertensive disorders of pregnancy","volume":"1","author":"Thadhani","year":"2022","journal-title":"NEJM-Evidence"},{"issue":"1\u20132","key":"10.1016\/j.emc.2025.03.008_bib22","article-title":"Pregnancy associated atypical hemolytic uremic syndrome triggered by massive uterine bleeding after outpatient dilatation and evacuation","volume":"6","author":"Tran","year":"2021","journal-title":"Journal of OncoNephrology (JON)"},{"issue":"19","key":"10.1016\/j.emc.2025.03.008_bib23","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1182\/blood.2020005221","article-title":"Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group","volume":"136","author":"Fakhouri","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.emc.2025.03.008_bib24","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1097\/AOG.0000000000003891","article-title":"Gestational Hypertension and Preeclampsia","volume":"135","year":"2020","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.emc.2025.03.008_bib25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/GRF.0000000000000253","article-title":"Diagnosis and management of HELLP syndrome complicated by liver hematoma","volume":"60","author":"Ditisheim","year":"2017","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.emc.2025.03.008_bib26","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0002-9378(99)70022-0","article-title":"The spectrum of severe preeclampsia: comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification","volume":"180","author":"James","year":"1999","journal-title":"Am J Obst Gyn"},{"issue":"1","key":"10.1016\/j.emc.2025.03.008_bib27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/10641955.2010.525277","article-title":"Standardized Mississippi protocol treatment of 190 patients with HELLP syndrome: slowing disease progression and preventing new major maternal morbidity","volume":"31","author":"Martin","year":"2011","journal-title":"Hypertens Pregnancy"},{"key":"10.1016\/j.emc.2025.03.008_bib28","article-title":"Drug-induced thrombotic microangiopathy: an updated review of causative drugs, pathophysiology, and management","volume":"13","author":"Mazzierli","year":"2022","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.emc.2025.03.008_bib29","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1111\/j.1600-6143.2008.02297.x","article-title":"Complement mutation-associated de novo thrombotic microangiopathy following kid- ney transplantation","volume":"8","author":"Le Quintrec","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.emc.2025.03.008_bib30","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1002\/ajh.26872","article-title":"Reeling in complement in transplant-associated thrombotic microangiopathy: you\u2019re going to need a bigger boat","volume":"98","author":"Jodele","year":"2023","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.emc.2025.03.008_bib31","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1200\/JCO.1989.7.6.781","article-title":"Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry","volume":"7","author":"Lesesne","year":"1989","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.emc.2025.03.008_bib32","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/1097-0142(19900801)66:3<587::AID-CNCR2820660330>3.0.CO;2-J","article-title":"Pulmonary tumor thrombotic microangiopathy with pulmonary hypertension","volume":"66","author":"Von Herbay","year":"1990","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.emc.2025.03.008_bib33","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/MD.0b013e3182603598","article-title":"Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases","volume":"91","author":"Lechner","year":"2012","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.emc.2025.03.008_bib34","article-title":"Finding of pathological thrombomodulin gene variant in a patient with idiopathic nodular glomerulosclerosis and chronic thrombotic microangiopathy-like changes","volume":"8","author":"Hanna","year":"2020","journal-title":"SAGE Open Med Case Rep"},{"issue":"1","key":"10.1016\/j.emc.2025.03.008_bib35","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000512227","article-title":"Complement-mediated thrombotic microangiopathy associated with lupus nephritis treated with eculizumab: a case report","volume":"11","author":"Torres","year":"2021","journal-title":"Case Rep Nephrol Dial"},{"issue":"4","key":"10.1016\/j.emc.2025.03.008_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2023.103706","article-title":"Therapeutic modalities in thrombotic thrombocytopenic purpura management among Jehovah\u2019s Witness patients: a review of reported cases","volume":"62","author":"Tran","year":"2023","journal-title":"Transfus Apher Sci"},{"issue":"3","key":"10.1016\/j.emc.2025.03.008_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2023.103656","article-title":"Caplacizumab as rescue therapy in refractory TTP involving neurologic features","volume":"62","author":"Tran","year":"2023","journal-title":"Transfus Apher Sci"},{"issue":"1","key":"10.1016\/j.emc.2025.03.008_bib38","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.transci.2018.01.003","article-title":"Cobalamin deficiency presenting with thrombotic microangiopathy (TMA) features: a systematic review","volume":"57","author":"Tran","year":"2018","journal-title":"Transfus Apher Sci"},{"issue":"5","key":"10.1016\/j.emc.2025.03.008_bib39","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.ajkd.2017.05.017","article-title":"Thrombotic microangiopathy: a multidisciplinary team approach","volume":"70","author":"Gordon","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1016\/j.emc.2025.03.008_bib40","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/ckj\/sfx081","article-title":"Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea","volume":"10","author":"Brocklebank","year":"2017","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.emc.2025.03.008_bib41","series-title":"Textbook of microbiology and immunology","article-title":"Complement system","author":"Parija","year":"2023"},{"issue":"22","key":"10.1016\/j.emc.2025.03.008_bib42","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1200\/JCO.21.02389","article-title":"Narsoplimab, a mannan-binding lectin-associated serine protease-2 inhibitor, for the treatment of adult hematopoietic stem-cell transplantation-associated thrombotic microangiopathy","volume":"40","author":"Khaled","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.emc.2025.03.008_bib43","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ndt\/gfw453","article-title":"Eculizumab in secondary atypical haemolytic uraemic syndrome","volume":"32","author":"Cavero","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.emc.2025.03.008_bib44","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000492033","article-title":"When to stop eculizumab in complement-mediated thrombotic microangiopathies","volume":"48","author":"Olson","year":"2018","journal-title":"Am J Nephrol"}],"container-title":["Emergency Medicine Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733862725000197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733862725000197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T22:46:32Z","timestamp":1751409992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733862725000197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0733862725000197"],"URL":"https:\/\/doi.org\/10.1016\/j.emc.2025.03.008","relation":{},"ISSN":["0733-8627"],"issn-type":[{"value":"0733-8627","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombotic Microangiopathies","name":"articletitle","label":"Article Title"},{"value":"Emergency Medicine Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.emc.2025.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}